Aberdeen Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Aberdeen Group’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-40,812	Closed	-$4.72M	–	993
2023 Q3	$4.72M	Sell	40,812 -16,941	-29%	-$1.82M	0.01%	564
2023 Q2	$5.94M	Sell	57,753 -103,911	-64%	-$11M	0.01%	549
2023 Q1	$17.6M	Sell	161,664 -1,684,822	-91%	-$186M	0.04%	369
2022 Q4	$210M	Sell	1,846,486 -69,431	-4%	-$5.77M	0.57%	36
2022 Q3	$119M	Sell	1,915,917 -183,607	-9%	-$12.8M	0.35%	64
2022 Q2	$171M	Buy	2,099,524 +10,798	+0.5%	+$1.02M	0.54%	41
2022 Q1	$221M	Buy	2,088,726 +258,346	+14%	+$25.2M	0.57%	40
2021 Q4	$197M	Sell	1,830,380 -42,486	-2%	-$4.63M	0.43%	58
2021 Q3	$205M	Buy	1,872,866 +56,265	+3%	+$5.84M	0.46%	52
2021 Q2	$170M	Sell	1,816,601 -77,600	-4%	-$7.14M	0.37%	67
2021 Q1	$174M	Buy	1,894,201 +134,636	+8%	+$11.4M	0.4%	66
2020 Q4	$129M	Sell	1,759,565 -284,978	-14%	-$21.2M	0.31%	79
2020 Q3	$159M	Sell	2,044,543 -78,734	-4%	-$5.42M	0.42%	64
2020 Q2	$118M	Sell	2,123,277 -146,241	-6%	-$6.26M	0.32%	82
2020 Q1	$67.2M	Buy	2,269,518 +429,800	+23%	+$14.5M	0.21%	99
2019 Q4	$66.6M	Buy	1,839,718 +346,321	+23%	+$10.6M	0.16%	111
2019 Q3	$40.7M	Buy	+1,493,397	New	+$38.6M	0.1%	169

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Aberdeen Group's HZNP Position: Q4 2023 in Review

Aberdeen Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 40,812 shares — an estimated $4.72M sold.

Aberdeen Group first reported a position in HZNP in Q3 2019 and held it in 17 quarters. The position peaked at $221M in Q1 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Aberdeen Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Aberdeen Group sold 40,812 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $4.72M.
Aberdeen Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2019 and held it in 17 quarters.
Aberdeen Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $221M in Q1 2022.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Aberdeen Group's 13F filing for Q4 2023, filed 31 Jan 2024.